|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0020314,
umls-concept:C0205531,
umls-concept:C0226896,
umls-concept:C0243077,
umls-concept:C0442027,
umls-concept:C0723595,
umls-concept:C0796679,
umls-concept:C0935763,
umls-concept:C1412186,
umls-concept:C1527415,
umls-concept:C1880355
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2008-1-9
|
|
pubmed:abstractText |
Beta-benzamido hydroxamic acids were discovered as potent TACE inhibitors. A computer model was constructed to help understanding the binding activities and guiding SAR study. SAR optimization led to the discovery of compound 30 which met all in vitro and in vivo criteria for the program and was selected for further evaluation.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
1464-3405
|
|
pubmed:author |
pubmed-author:ChenLihuaL,
pubmed-author:ChristDavid DDD,
pubmed-author:CovingtonMaryanne BMB,
pubmed-author:DeciccoCarl PCP,
pubmed-author:DuanJames J-WJJ,
pubmed-author:LiuRui-QinRQ,
pubmed-author:LuZhonghuiZ,
pubmed-author:NewtonRobert CRC,
pubmed-author:QianMingxinM,
pubmed-author:TrzaskosJames MJM,
pubmed-author:VaddiKrishnaK,
pubmed-author:WassermanZelda RZR,
pubmed-author:XueChu-BiaoCB
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
1
|
|
pubmed:volume |
18
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
241-6
|
|
pubmed:meshHeading |
pubmed-meshheading:18032037-ADAM Proteins,
pubmed-meshheading:18032037-Administration, Oral,
pubmed-meshheading:18032037-Animals,
pubmed-meshheading:18032037-Benzamides,
pubmed-meshheading:18032037-Binding Sites,
pubmed-meshheading:18032037-Biological Availability,
pubmed-meshheading:18032037-Dogs,
pubmed-meshheading:18032037-Hydroxamic Acids,
pubmed-meshheading:18032037-Models, Molecular,
pubmed-meshheading:18032037-Protease Inhibitors,
pubmed-meshheading:18032037-Rats,
pubmed-meshheading:18032037-Rats, Sprague-Dawley,
pubmed-meshheading:18032037-Structure-Activity Relationship,
pubmed-meshheading:18032037-Swine
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
Discovery of beta-benzamido hydroxamic acids as potent, selective, and orally bioavailable TACE inhibitors.
|
|
pubmed:affiliation |
Research and Development, Bristol-Myers Squibb Company, Princeton, NJ 08543-4000, USA. james.duan@bms.com
|
|
pubmed:publicationType |
Journal Article
|
